6,573 Shares in Candel Therapeutics, Inc. (NASDAQ:CADL) Acquired by Fmr LLC

Fmr LLC acquired a new position in shares of Candel Therapeutics, Inc. (NASDAQ:CADL) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 6,573 shares of the company’s stock, valued at approximately $46,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of CADL. Point72 DIFC Ltd acquired a new stake in shares of Candel Therapeutics in the second quarter worth $31,000. Rhumbline Advisers bought a new stake in Candel Therapeutics in the 2nd quarter valued at $143,000. Cubist Systematic Strategies LLC acquired a new stake in Candel Therapeutics in the 2nd quarter worth $162,000. Finally, Bank of New York Mellon Corp bought a new position in shares of Candel Therapeutics during the 2nd quarter worth about $338,000. 13.93% of the stock is currently owned by institutional investors and hedge funds.

Candel Therapeutics Trading Up 2.0 %

CADL opened at $8.80 on Thursday. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 1.66. Candel Therapeutics, Inc. has a 12 month low of $1.10 and a 12 month high of $14.60. The stock has a market capitalization of $285.79 million, a P/E ratio of -5.09 and a beta of -0.95. The firm’s fifty day simple moving average is $5.62 and its 200 day simple moving average is $6.06.

Insider Buying and Selling

In related news, CTO Seshu Tyagarajan sold 20,392 shares of the business’s stock in a transaction on Friday, November 29th. The shares were sold at an average price of $4.56, for a total transaction of $92,987.52. Following the transaction, the chief technology officer now owns 125,657 shares in the company, valued at $572,995.92. The trade was a 13.96 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider William Garrett Nichols sold 13,935 shares of the company’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $4.56, for a total value of $63,543.60. Following the transaction, the insider now directly owns 100,547 shares in the company, valued at $458,494.32. The trade was a 12.17 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 66,127 shares of company stock valued at $349,911. Insiders own 41.60% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and issued a $19.00 target price (up from $11.00) on shares of Candel Therapeutics in a research note on Wednesday, December 18th.

About Candel Therapeutics

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.